Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2006; 48:1871-1879, doi:10.1016/j.jacc.2006.07.036 (Published online 16 October 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2006.07.036v1
48/9/1871    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, S.-L.
Right arrow Articles by Wu, H.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, S.-L.
Right arrow Articles by Wu, H.-L.

PRECLINICAL STUDY

A Novel Inhibitory Effect of Naloxone on Macrophage Activation and Atherosclerosis Formation in Mice

Shu-Lin Liu, MS*,{dagger}, Yi-Heng Li, MD, PhD{ddagger},§, Guey-Yueh Shi, PhD*,{ddagger}, Yung-Huan Chen, MS*, Chia-Wei Huang, MS*,{dagger}, Jau-Shyong Hong, PhD|| and Hua-Lin Wu, PhD*,{ddagger},*

* Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
{dagger} Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
{ddagger} Cardiovascular Research Center, College of Medicine, National Cheng Kung University, Tainan, Taiwan
§ Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
|| Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina

Manuscript received April 13, 2006; revised manuscript received June 6, 2006, accepted July 3, 2006.

* Reprint requests and correspondence: Dr. Hua-Lin Wu, Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan. (Email: halnwu{at}mail.ncku.edu.tw).

OBJECTIVES: We investigated whether naloxone could reduce macrophage activation and influence atherosclerotic lesion formation in mice.

BACKGROUND: Macrophages play an important role in the inflammatory process in atherosclerosis. Naloxone could inhibit activation of microglia, the resident macrophage in the nervous system.

METHODS: The anti-inflammatory effect of naloxone was evaluated by stimulating the macrophage cell culture and FVB mice with lipopolysaccharide or oxidized low-density lipoprotein with and without naloxone pretreatment. Apolipoprotein-E (apoE)-deficient mice received naloxone injection for 10 weeks, and the severity of aortic atherosclerosis was measured. The left common carotid arteries of C57BL/6 mice were ligated near the carotid bifurcation. The mice then received naloxone injection for 4 weeks after ligation, and the severity of neointima formation was evaluated.

RESULTS: Naloxone pretreatment significantly suppressed the production of tumor necrosis factor-{alpha} (TNF-{alpha}), interleukin-6, monocyte chemoattractant protein-1, and superoxide in macrophages after stimulation. In FVB mice, naloxone reduced the TNF-{alpha} level in circulation, inflammatory cell infiltration in lungs, and superoxide production in aorta. Naloxone injection significantly decreased the severity of aortic atherosclerosis in the apoE-deficient mice and carotid neointima formation in the C57BL/6 mice after ligation.

CONCLUSIONS: Naloxone, with its novel anti-inflammatory effect, significantly reduces atherosclerosis and neointima formation in mice.

Abbreviations and Acronyms
  apoE = apolipoprotein-E
  DHE = dihydroethidium
  EEL = external elastic lamina
  ELISA = enzyme-linked immunosorbent assay
  HDL = high-density lipoprotein
  IEL = internal elastic lamina
  IL-6 = interleukin-6
  LPS = lipopolysaccharide
  MCP-1 = monocyte chemoattractant protein-1
  MTT = 3 (4,5-dimethylthiazol-2-yl) 2, 5-diphenyltetrazolium bromide
  NADPH = nicotinamide adenine dinucleotide phosphate
  N/M = neointima/media area ratio
  oxLDL = oxidized low-density lipoprotein
  PBS = phosphate-buffered saline
  RLU = relative light units
  THP-1 = human acute monocytic leukemia cell line
  TNF-{alpha} = tumor necrosis factor-{alpha}




This article has been cited by other articles:


Home page
Circ. Res.Home page
Y. Etzion, A. Hackett, B. M. Proctor, J. Ren, B. Nolan, T. Ellenberger, and A. J. Muslin
An Unbiased Chemical Biology Screen Identifies Agents That Modulate Uptake of Oxidized LDL by Macrophages
Circ. Res., July 17, 2009; 105(2): 148 - 157.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S.-L. Liu, Y.-H. Li, G.-Y. Shi, S.-H. Tang, S.-J. Jiang, C.-W. Huang, P.-Y. Liu, J.-S. Hong, and H.-L. Wu
Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice
Cardiovasc Res, April 1, 2009; 82(1): 161 - 169.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol., January 30, 2007; 49(4): 509 - 527.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement